3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
69
Neoplasms
28
Neoplasm Metastasis
14
Colorectal Neoplasms
9
Multiple Myeloma
6
Thyroid Neoplasms
5
Skin Neoplasms
5
Lymphoma, Non-Hodgkin
5
Carcinoma, Non-Small-Cell Lung
5
Thyroid Cancer, Papillary
4
Leukemia, Hairy Cell
4
Hematologic Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Breast Neoplasms
3
Wilms Tumor
2
Thyroid Carcinoma, Anaplastic
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma
2
Interventions
Cisplatin
35
Radiotherapy
20
Magnetic Resonance Spectroscopy
19
Cetuximab
17
Specimen Handling
15
pembrolizumab
13
Carboplatin
13
Radiotherapy, Intensity-Modulated
12
Fluorouracil
12
Docetaxel
12
1,2-diaminocyclohexaneplatinum II citrate
10
Radiation
9
Platinum
9
Paclitaxel
8
Surgical Procedures, Operative
7
Drug Therapy
6
Biopsy
6
Taxes
5
toripalimab
4
X-Rays
4
Standard of Care
4
Fluorodeoxyglucose F18
4
Celecoxib
4
(225)Ac-DOTA-c(RGDyK)
4
cemiplimab
3
Nutritional Status
3
Laser Therapy
3
Interviews as Topic
3
Hydroxyurea
3
130-nm albumin-bound paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Laryngeal Neoplasms
×
Vemurafenib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled